Aller au contenu principal
ProhibitedBinding ruleKRNo English translationImport de la source officielle contrôlé

덱스트로메토르판 및 그 염류

Listed by the Korean MFDS as a substance that may not be used in cosmetics.

Décision réglementaire et conditions complètes

Statut
Prohibited
Rôle juridique
Binding rule
Résumé réglementaire
Listed by the Korean MFDS as a substance that may not be used in cosmetics.
Conditions et restrictions

덱스트로메토르판

Identité de la substance

Nom dans la source officielle
덱스트로메토르판 및 그 염류
CAS
125-71-3
EC
Not supplied in this source row
Correspondance d’identité
standalone:official_korean_name

Aperçu multi-marchés pour cette identité

Fiches exactes associées actuellement présentes sur ce site. L’absence d’un marché signifie qu’aucune correspondance exacte n’a été importée, et non une autorisation d’utiliser la substance.

10 jeux de données de marchés
Structure chimique 2D PubChem pour le CAS 125-71-3
CAS 125-71-3PubChem CID 5360696

Chimie vérifiée pour le CAS 125-71-3

Dextromethorphan

Dextromethorphan is a 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough. It has a role as a oneirogen, a xenobiotic, a prodrug, a neurotoxin, an antitussive, a NMDA receptor antagonist and an environmental contaminant. It is functionally related to a dextrorphan. It is an enantiomer of a levomethorphan. — ChEBI

Nom IUPAC
(1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
Formule moléculaire
C18H25NO
Masse moléculaire
271.4 g/mol
Masse exacte
271.193614421 Da
Masse monoisotopique
271.193614421 Da
XLogP3
3,4
Surface polaire topologique
12,5 Ų
Complexité moléculaire
370,0
Charge formelle
0
Donneurs de liaisons hydrogène
0
Accepteurs de liaisons hydrogène
2
Liaisons rotatives
1
Atomes lourds
20
Unités covalentes
1

Noms et synonymes signalés à PubChem

d-Methorphandelta-MethorphanDextromorphanDextromethorfanDextrometorfanoDextromethorphaneAlbutussinDestrometerfano
16 autres noms signalés
DextromethorphanumBA 2666Balminil DM(+)-Dextromethorphan3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinanMorphinan, 3-methoxy-17-methyl-, (9alpha,13alpha,14alpha)-DXM [Antitussive]BA-26667355X3ROTSCHEBI:4470(+)-3-Methoxy-N-methylmorphinonNSC-751452DXM (Antitussive)(+)-cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren(+)-3-methoxy-17-methyl-9alpha,13alpha,14alpha-morphinanRoboTablets
Identifiants de bases de données externes
Statistiques de structure avancées
Stéréocentres atomiques définis
3
Stéréocentres atomiques non définis
0
Stéréocentres de liaison définis
0
Stéréocentres de liaison non définis
0
Caractéristiques pharmacophoriques 3D
6
Cycles 3D
4
Groupes hydrophobes 3D
0
Caractéristiques d’accepteur 3D
1
Caractéristiques de donneur 3D
0
Centres anioniques 3D
0
Centres cationiques 3D
1
Conformères 3D
2
Rotors 3D effectifs
2,6
Identifiants de structure lisibles par machine
SMILES
CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
InChI
InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1
InChIKey
MKXZASYAUGDDCJ-NJAFHUGGSA-N

Preuves issues de bases de données scientifiques complémentaires

NIH PubChem PUG-View
Correspondance exacte d’identifiant5360696

Attributed physical-property, hazard, environmental and use annotations.

  • Note: This chemical does not meet GHS hazard criteria for 46.8% (36 of 77) of reports. Source: European Chemicals Agency (ECHA)
  • Signal: Danger Source: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H301 (51.9%): Toxic if swallowed [Danger Acute toxicity, oral] Source: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 77 reports by companies from 4 notifications to the ECHA C&L Inventory.; Reported as not meeting GHS hazard criteria per 36 of 77 reports by companies.; There are 3 notifications provided by 41 of 77 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
  • Toxicity Summary: IDENTIFICATION AND USE: Dextromethorphan is a white odorless solid crystal or powder. It is an opium alkaloid derivative, which is found in cough and cold preparations. HUMAN STUDIES: Dextromethorphan is a drug of abuse. The main risks associated with dextromethorphan are ataxia, central nervous system (CNS) stimulation, dizziness, lethargy and psychotic behavior. Less frequently with large doses seizures and respiratory depression can occur. Nausea, vomiting, constipation and tachycardia may also occur. CNS effects include ataxia, drowsiness, vertigo and rarely coma. CNS stimulation may be observed. Restlessness, increased muscle tone with body rigidity have been reported. With extremely large ingestions respiratory depression can occur. Gastrointestinal effects include nausea, vomiting, constipation and dry mouth. Urinary retention may be seen. Dextromethorphan abuse has been described and produces euphoria, CNS stimulation, visual and/or auditory hallucinations. Dextromethorphan hydrobromide is the drug form, thus the possibility of bromide poisoning should be considered in the long term abuser. Dextromethorphan enhances serotonin activity by inhibiting the reuptake of serotonin Source: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: Signs and Symptoms of Overdose; One significant concern regarding dextromethorphan toxicity is its OTC misuse, which has steadily increased since the early 2000s. This misuse is referred to by slang terms such as "going pharming," "robotripping," and "dexing." In 2006, three specific OTC product formulations accounted for 66% of reported dextromethorphan misuse cases in the United States, with Coricidin HBP Cough & Cold Tablets and Robitussin products being prominent. A life-threatening toxicity associated with dextromethorphan abuse is serotonin syndrome, resulting from its serotonin reuptake inhibition properties. When combined with SSRIs or MAOIs, the risk of serotonin syndrome increases significantly. Symptoms include agitation, confusion, dilated pupils, headache, tachycardia, hypotension, high fever, seizures, irregular heartbeat, and may progress to unconsciousness.; Despite the rise in misuse, public health efforts and legislative actions restricting the sale of dextromethorphan-containing products to minors have helped stabilize or reduce abuse rates in recent years. However, continued vigilance is essential to prevent misuse and associated toxicities, given dextromethorph Source: StatPearls
  • Toxicity Summary: Dextromethorphan is an opioid-like drug that binds to and acts as antagonist to the NMDA glutamatergic receptor, it is an agonist to the opioid sigma 1 and sigma 2 receptors, it is also an alpha3/beta4 nicotinic receptor antagonist and targets the serotonin reuptake pump. Dextromethorphan is rapidly absorbed from the gastrointestinal tract, where it enters the bloodstream and crosses the blood-brain barrier. The first-pass through the hepatic portal vein results in some of the drug being metabolized into an active metabolite of dextromethorphan, dextrorphan, the 3-hydroxy derivative of dextromethorphan. Source: Toxin and Toxin Target Database (T3DB)
  • Environmental Bioconcentration: The estimated pKa of dextromethorphan is 9.8(1), indicating that dextromethorphan will exist almost entirely in the cation form at pH values of 5 to 9 and, therefore, bioconcentration in fish is not expected to be an important fate process(SRC). Source: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 23,000(SRC), determined from a structure estimation method(2), indicates that dextromethorphan is expected to be immobile in soil(SRC). The estimated pKa of dextromethorphan is 9.8(3), indicating that this compound will exist almost entirely in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization of the cation from moist soil is not expected because cations do not volatilize(SRC). Dextromethorphan is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.0X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2017). Source: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 23,000(SRC), determined from a structure estimation method(2), indicates that dextromethorphan is expected to adsorb to suspended solids and sediment(SRC). An estimated pKa of 9.8(3) indicates dextromethorphan will exist almost entirely in the cation form at pH values of 5 to 9 and, therefore, volatilization from water surfaces and bioconcentration in aquatic organisms are not expected to be an important fate processes(SRC). Dextromethorphan is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(4). Biodegradation data in water were not available(SRC, 2017). Source: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), dextromethorphan, which has an estimated vapor pressure of 1.0X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase dextromethorphan is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 3.3 hours(SRC), calculated from its rate constant of 1.2X10-10 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(2). Particulate-phase dextromethorphan may be removed from the air by wet or dry deposition(SRC). Dextromethorphan contains chromophores that absorb at wavelengths >290 nm(3) and, therefore, is expected to be susceptible to direct photolysis by sunlight(SRC). Source: Hazardous Substances Data Bank (HSDB)
  • Uses: Antitussive Agents; Excitatory Amino Acid Antagonists Source: Hazardous Substances Data Bank (HSDB)
  • Uses: Probe to determine cytochrome 450 phenotype Source: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION Source: Hazardous Substances Data Bank (HSDB)
  • Uses: Dextromethorphan (DXM) is an over-the-counter (OTC) cough suppressant commonly found in cold medications. DXM is often abused in high doses by adolescents to generate euphoria and visual and auditory hallucinations. Illicit use of DXM is referred to on the street as "Robo-tripping" or "skittling." These terms are derived from the most commonly abused products, Robitussin and Coricidin. Source: Hazardous Substances Data Bank (HSDB)
  • Uses: Use (kg; approx.) in Germany (2009): >1000; Use (kg) in USA (2002): 38000; Consumption (g per capita; approx.) in Germany (2009): 0.0122; Consumption (g per capita) in the USA (2002): 0.135; Excretion rate: 0.25; Calculated removal (%): 45.3 Source: NORMAN Suspect List Exchange
  • Uses: The primary use of dextromethorphan is as a cough suppressant, for the temporary relief of cough caused by minor throat and bronchial irritation (as commonly accompanies the common cold), as well as those resulting from inhaled irritants. In addition, a combination of dextromethorphan and quinidine has been shown to alleviate symptoms of easy laughing and crying (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis. Source: Toxin and Toxin Target Database (T3DB)

Mis en correspondance par: Existing checksum-valid CAS to unique PubChem CID match. Récupéré le: 2026-08-31. Ouvrir la fiche source

Les classifications scientifiques et les annotations de danger apportent du contexte et ne remplacent pas la décision réglementaire propre au marché indiquée ci-dessus.

Couverture des sources complémentaires et état des correspondances
SourceRésultatVérifié
NIH PubChem PUG-ViewCorrespondance exacte2026-08-31

Une absence de correspondance enregistrée est une preuve utile que la source a été vérifiée ; ce n’est pas l’affirmation que la substance n’existe pas ailleurs.

Récupéré depuis NIH PubChem le 2026-08-31 par correspondance CAS à somme de contrôle valide. Les propriétés chimiques ne remplacent pas la décision réglementaire de cette page.

Source officielle et provenance

Source enregistrée
South Korea MFDS cosmetic ingredient data
Référence de la source
화장품 안전기준 등에 관한 규정, 별표 1, record 1-92
Identifiant de la fiche source
1-92
Version de la source
2026-19
Langue de la source
Korean
État de la traduction
No English translation
Date d’effet
2026-03-18
Source mise à jour le
2026-03-18
Instantané vérifié le
2026-08-30 04:33 UTC
Méthode de validation
MFDS JSON appendices 1–2 parse; 1077 prohibited, 243 restricted
SHA-256
056de35b843a5e31f709073f9e79d5e6e18f7c9164eb537bb099b185a37ef7d8

Notes du jeu de données enregistré

Couverture du jeu de données
Ingredient identity and separate restriction/regulation data endpoints
Note sur l’autorité
Korean source is canonical; English materials alone are not complete enough for certification

Place de cette fiche dans le jeu de données du marché

1320
fiches South Korea actuelles
1077
fiches marquées Prohibited
1320
fiches de cette version de la source
1252
fiches du marché avec identité CAS

Répartition des statuts

Un texte de conditions est présent pour 638 des 1320 fiches actuelles. Un champ de conditions vide est interprété selon le type de fiche ci-dessus ; il n’est jamais converti en une affirmation d’utilisation sans restriction.

South Korea contexte du marché

Complete current appendix dataset

Version de la couverture : MFDS Notice 2026-19, effective 18 March 2026

All rows in official Appendix 1 (prohibited) and Appendix 2 (restricted) of the Safety Standards for Cosmetics.

Liste de contrôle de vérification

  1. Match the Korean canonical substance name and identifiers.
  2. Review all Appendix 1 and 2 matches and conditions.
  3. Check functional-cosmetic and positive-list requirements where applicable.
  4. Confirm current MFDS notice, responsible seller and label obligations.

Sources officielles du marché

Procédure de vérification et exhaustivité de la fiche

Avant d’utiliser ce résultat dans une décision de conformité

  1. Confirmez que « 덱스트로메토르판 및 그 염류 » et chaque identifiant CAS/CE correspondent à la matière de votre spécification fournisseur.
  2. Match the Korean canonical substance name and identifiers.
  3. Review all Appendix 1 and 2 matches and conditions.
  4. Check functional-cosmetic and positive-list requirements where applicable.
  5. Confirm current MFDS notice, responsible seller and label obligations.
  6. Consignez la version de la source et revérifiez auprès de l’autorité de réglementation avant la fabrication, la notification ou la mise sur le marché.

Champs disponibles dans cette fiche

  • Nom officiel de la substanceDisponible
  • CASDisponible
  • ECNon fourni
  • Texte de condition distinctDisponible
  • Date d’effetDisponible
  • Empreinte de l’instantané et méthodeDisponible

Questions auxquelles cette page répond

This official record identifies the substance as prohibited for cosmetic use in the stated market scope. Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. Korean source wording is canonical and other positive lists/notices may still apply to the formulation.

La fiche cite 화장품 안전기준 등에 관한 규정, 별표 1, record 1-92, version de la source 2026-19. Ouvrir la source officielle.

Non. Le CAS aide à déterminer l’identité, mais les juridictions peuvent classer différemment une même substance et appliquer des champs d’application, limites, avertissements et dates de transition différents.

Citation stable

덱스트로메토르판 및 그 염류. 화장품 안전기준 등에 관한 규정, 별표 1, record 1-92. South Korea. Source version 2026-19. CosIng Checker regulatory record: https://cosingchecker.com/fr/regulations/kr/records/885/

Citez l’autorité de réglementation comme autorité juridique. Cette page est un index structuré de preuves et une aide à la vérification, et non un substitut au texte officiel ni à une évaluation juridique professionnelle.

Interprétation et limites pour South Korea

This official record identifies the substance as prohibited for cosmetic use in the stated market scope.

Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

Comment interpréter le rôle juridique

The cited row forms part of a binding rule or legally incorporated list for this market.

Preuves sur cette page

  • Résultat enregistré : Prohibited
  • Rôle juridique : Binding rule
  • Version de la source : 2026-19
  • Date d’effet : 2026-03-18

Ce que cela ne prouve pas

Korean source wording is canonical and other positive lists/notices may still apply to the formulation.

Recherche complémentaire sur la substance auprès de sources faisant autorité

Aucune de ces sources ne prévaut sur la décision de marché ci-dessus.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

Rechercher cette identité à la source

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

Rechercher cette identité à la source

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

Rechercher cette identité à la source

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

Rechercher cette identité à la source

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

Rechercher cette identité à la source

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

Rechercher cette identité à la source

US EPA CompTox CTX APIs

Clé d’API requise pour l’import

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

Rechercher cette identité à la source